CytoSorbents Expands Global Footprint with Opening of New Regional Sales Subsidiary in Dubai

Core Insights - CytoSorbents Corporation has opened a new regional sales subsidiary in Dubai, UAE, marking a significant step in its expansion strategy into the Middle East and Africa [1][2] - The new subsidiary aims to enhance sales growth, support existing partnerships, and foster new alliances in a region with increasing demand for advanced medical technologies [2][3] Company Overview - CytoSorbents is a leader in treating life-threatening conditions in intensive care and cardiac surgery through blood purification technologies [3][4] - The company's proprietary technology utilizes biocompatible polymer beads to remove toxic substances from blood, with applications in various critical illnesses [3][4] Product Information - The lead product, CytoSorb, is approved in the European Union and distributed in 76 countries, with over 250,000 devices used to date [4] - CytoSorb has received FDA Emergency Use Authorization for critically ill COVID-19 patients in the U.S. but is not yet fully approved [4] Development Initiatives - CytoSorbents is developing the DrugSorb-ATR system to reduce perioperative bleeding in high-risk surgeries, which has received FDA Breakthrough Device Designations [5][6] - The company has submitted a De Novo medical device application to the U.S. FDA for marketing approval of DrugSorb-ATR [6] Strategic Location - The new commercial office is located in Dubai's Science Park, a healthcare-focused free zone, chosen for its strategic location and favorable economic conditions [2][3]